Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rare Diseases And Beyond: FDA Seeks Input On Establishing Clinical Trial Networks

Executive Summary

US FDA is looking for advice on how to design a clinical trial network to complete the third component of its Rare Disease Cures Accelerator Program, but it also wants advice on clinical trial networks more broadly. The rare disease network will need to be global given the more limited patient populations, the agency said.

You may also be interested in...



Rare Disease Cures Accelerator Expected To Drive Lots Of Development – Eventually

Clinical Outcome Assessments To Be Developed Under US FDA Grants

The projects could help streamline rare disease drug development, along with the Rare Disease Cures Accelerator.

Califf Clears First Senate Hurdle, But FDA Decision On Abortion Pill May Complicate Final Confirmation

Republican opposition to Califf over agency’s recent move to relax its Mifeprex restrictions is ominous since, in order be confirmed as commissioner, he’ll need enough GOP votes to make up for Democratic opposition over his opioid track record and connections to pharma industry.

Topics

UsernamePublicRestriction

Register

PS142283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel